Je. Henriksen et al., Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients, DIABETES, 49(7), 2000, pp. 1209-1218
With the aim of investigating glucose-mediated glucose disposal (glucose ef
fectiveness [GE]) in 15 (3 female and 12 male subjects) insulin-resistant n
ormoglycemic relatives of patients with type 2 diabetes (DM2), and 15 age-,
sex-, and BMI-matched control subjects without a family history of DM2, we
performed 2 studies: 1) a 5-h euglycemic near-normoinsulinemic pancreatic
clamp with somatostatin (360 mu g/h), insulin (0.25 mU . kg(-1) . min(-1)),
glucagon (0.5 ng . kg(-1) . min(-1)), growth hormone (6 ng . kg(-1) . min(
-1)), and tritiated glucose infusion and indirect calorimetry; and 2) on a
separate day, an identical 5-h clamp but at hyperglycemia (similar to 12 mm
ol/l) over the last 2 h. Pasting plasma insulin (PI) concentrations were el
evated in the relatives compared with control subjects (49 +/- 6 vs. 32 +/-
5 pmol/l, P < 0.04), whereas plasma glucose (PG) was not (5.6 +/- 0.1 vs.
5.5 +/- 0.1 mmol/l). At the end (i.e., 4.5-5.0 h) of the euglycemic clamp (
PG, 6.1 +/- 0.4 vs. 5.6 +/- 0.1 mmol/l; PI, 78 +/- 5 vs. 73 +/- 6 pmol/l),
peripheral glucose uptake (Rd(euglycemia)) was decreased in the relatives (
2.93 +/- 0.08 vs. 3.70 +/- 0.23 mg . min(-1) . kg(-1) fat free mass [FFM],
P < 0.005), due to a decreased nonoxidative glucose disposal (0.83 +/- 0.21
vs. 1.62 +/- 0.19 mg . min(-1) . kg(-1) FFM, P < 0.01), but hepatic glucos
e production (HGP) was increased (1.97 +/- 0.19 vs. 1.50 +/- 0.13 mg . min(
-1) . kg(-1) FFM, P < 0.05). At the matched end of the hyperglycemic clamp
(PG, 12.7 +/- 0.2 vs. 12.6 +/- 0.2 mmol/l; PI, 87 +/- 5 vs. 78 +/- 7 pmol/l
), peripheral glucose disposal (Rd(hyperglycemia)) (5.52 +/- 0.22 vs. 5.92
+/- 0.29 mg . min(-1) . kg(-1) FFM, NS), nonoxidative glucose disposal (2.9
3 +/- 0.18 vs. 2.78 +/- 0.25 mg . min(-1) . kg(-1) FFM, NS), and HGP(hyperg
lycemia) (1.20 +/- 0.09 vs. 1.37 +/- 0.23 mg . min(-1) . kg(-1) FFM, NS) we
re all identical. When the effectiveness of glucose itself on glucose uptak
e and production [(Rd(hyperglycemia) - Rd(euglycemia))/Delta PG and (HGP(eu
glycemia) - HGP(hyperglycemia))/Delta PG] was calculated, the relatives had
a 22% increase in peripheral uptake (0.022 +/- 0.002 vs. 0.018 +/- 0.002 m
g . min(-1) . kg(-1) FFM per mg/dl), due to a significantly increased nonox
idative glucose metabolism and enhanced suppression of HGP (0.0076 +/- 0.00
21 vs. 0.0011 +/- 0.0022 mg . min(-1) . kg(-1) FFM per mg/dl, P < 0.05). In
conclusion, in insulin-resistant relatives of DM2 patients, whole-body glu
cose-mediated glucose disposal is increased by GE enhancement of the muscle
nonoxidative glucose pathway and by GE enhancement of the suppression of H
GP. These mechanisms may represent a compensatory mechanism to the ongoing
insulin resistance of these relatives.